R K G Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 3.00 M
- Company Age 55 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.13 Cr
- Satisfied Charges ₹ 2.70 M
- Revenue Growth -18.55%
- Profit Growth -7.79%
- Ebitda -6.75%
- Net Worth 9.12%
- Total Assets -3.51%
About R K G Pharma
R K G Pharma Pvt Ltd (RKGPPL) was founded in India on 16 August 1969 and has a glorious history of 55 years and five months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 3.00 M.
The company currently has active open charges totaling ₹3.13 Cr. The company has closed loans amounting to ₹2.70 M, as per Ministry of Corporate Affairs (MCA) records.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74899DL1969PTC005111
-
Company No.
005111
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Aug 1969
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at R K G Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjeev Garg
|
Director | 01-Jun-1986 | Current |
|
Preeti Garg
|
Director | 15-Oct-2021 | Current |
Financial Performance of R K G Pharma.
R K G Pharma Pvt Ltd, for the financial year ended 2021, experienced significant reduction in revenue, with a 18.55% decrease. The company also saw a slight decrease in profitability, with a 7.79% decrease in profit. The company's net worth moved up by a moderate rise of 9.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of R K G Pharma?
In 2021, R K G Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Medlar Pharmachem Private LimitedPreeti Garg is a mutual person
Charges (Loans)
₹3.13 Cr
₹0.27 Cr
Charges Breakdown by Lending Institutions
- Dena Bank : 2.79 Cr
- Dena Bank : 0.27 Cr
- Deena Bank : 0.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 08 Apr 2005 | Dena Bank | ₹2.70 M | Open |
| 14 Jan 2004 | Dena Bank | ₹8.00 M | Open |
| 01 May 2000 | Dena Bank | ₹8.00 M | Open |
| 06 Apr 2000 | Dena Bank | ₹1.10 Cr | Open |
| 29 Sep 1992 | Deena Bank | ₹0.46 M | Open |
How Many Employees Work at R K G Pharma?
R K G Pharma has a workforce of 22 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of R K G Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped R K G Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
